ICMS (International Cellular Medicine Society” is a 501c3 non-profit that we, among others have helped to form. It has taken on a life of it’s own, with it’s executive director, David Audley doing a great job of taking the reigns and expanding it’s mission of safe and effective, physician delivered stem cell treatments. In this case, above is a slide from a training presentation on how ICMS will begin entering data into the open treatment registry for patients in Korea, being treated by a Korean company (not associated with Regenexx). ICMS, over the next few months, will also add stem cell clinics from other countries in Latin America. The addition of these clinics (who are not certified by ICMS at this point) that have agreed to have their complications and outcome data tracked by an independent third party non-profit marks a milestone for both physician managed stem cell therapy, but also ICMS and the science behind stem cell therapies in general. Observational databases (like the ICMS open stem cell registry) have been key in advancing many treatments such as bone marrow transplants and in-vitro fertilization. These databases help to guide which types of randomized controlled trials might yield the best results, improve safety for patients, and help in new therapy discovery. Congrats to ICMS for hitting this major milestone!
About the Author
Christopher J. Centeno, M.D. is an international expert and specialist in regenerative medicine and the clinical use of mesenchymal stem cells in orthopedics. He is board certified in physical medicine as well as rehabilitation and in pain management through The American Board of Physical Medicine and Rehabilitation.…